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Background. Coinfection with human immunodeﬁciency virus (HIV) and Leishmania donovani visceral leish-
maniasis (VL) in Africa is an emerging, poorly understood disease.
Methods. We evaluated 356 consecutive patients coinfected with HIV and VL treated in Humera, northwest
Ethiopia, from February 2003 to October 2006, for risk factors for VL relapse and death and the effect of
antiretroviral therapy (ART).
Results. During 2928 patient-months of follow-up, 256 VL episodes and 39 deaths occurred. Among 195
patients receiving ART, 31.3% had 1 VL episode, and 14.4% died. Among 161 patients who did not receive
ART, 26.1% had 1 VL episodes, and 6.8% died. A total of 54 patients who received ART and 58 patients who
did not receive ART had 1 VL relapse. VL relapse among patients receiving ART was associated with a baseline
CD4 cell count !100 cells/mL (hazard ratio [HR], 2.50; 95% conﬁdence interval [CI], 1.21–5.15) and 2 previous
VL episodes (HR, 3.74; 95% CI, 1.40–10.02). Failure to clear parasites after VL treatment was usually followed by
symptomatic VL relapse. Patients who relapsed showed poor CD4 cell count recovery while receiving ART. ART
was partially protective against VL relapse (HR, 0.46; 95% CI, 0.26–0.82). However, 28% of ﬁrst VL relapses while
receiving ART occurred despite a CD4 cell count 1200 cells/mL; in 5% of VL relapses, the CD4 cell count had
been 1200 cells/mL for 16 months. Factors associated with all-cause mortality among patients receiving ART were
baseline CD4 cell count !100 cells/mL (HR, 3.20; 95% CI, 1.30–7.87) and VL episodes during follow-up (HR for
1 episode, 4.97 [95% CI, 2.09–11.86]; HR for 12 episodes, 3.22 [95% CI, 1.01–10.23]).
Conclusions. Concordant HIV infection and VL is a major, acquired immunodeﬁciency syndrome–deﬁning
illness with high relapse and mortality rates; ART reduces relapses; and secondary antileishmanial prophylaxismay
beneﬁt patients at risk of relapse.
Visceral leishmaniasis (VL; also known as “kala-azar”)
is a systemic parasitic disease caused by the Leishmania
donovani species complex. An estimated 500,000 new
cases of VL occur annually [1]. In east Africa and south
Asia, the parasite is L. donovani, and the predominant
mode of transmission, via sandﬂies, is anthroponotic.
Humans with VL or post–kala-azar dermal leishman-
iasis provide the major reservoir for transmission;thus,
incomplete or irregular treatment of VL leads to drug
Received 30 November 2007; accepted 23 January2008;electronicallypublished
17 April 2008.
Reprints and correspondence: Simon M. Collin, Dept. of Social Medicine,
Canynge Hall, Whiteladies Rd., Bristol, BS8 2PR, United Kingdom (simon
.collin@bristol.ac.uk).
Clinical Infectious Diseases 2008;46:1702–9
  2008 by the Infectious Diseases Society of America. All rights reserved.
1058-4838/2008/4611-0009$15.00
DOI: 10.1086/587899
pressure and parasite resistance. In the Mediterranean
region and Latin America, a less-pathogenic zoonotic
parasite (Leishmania infantum, known as Leishmania
chagasi in Latin America) exists, causing infection in
dogs and sporadic VL cases in humans [2].
VL is typically fatal if untreated. In immunocom-
petent individuals, effective drug treatment reduces
Leishmania amastigotes to a level undetectable in as-
pirates. An effective life-long cellular immune response
normally develops, and residual parasites are sup-
pressed unless immunodeﬁciency is present [3]. HIV
infection can lead to reactivation of latent Leishmania
infection or to symptomatic VL at initial infection; in
Europe, the risk of developing VL is 100–1000 times
greater for HIV-infected individuals than for HIV-un-
infected individuals [4, 5]. VL accelerates HIV repli-
cation and disease progression, mainly by chronic im-
mune stimulation [6]. The prevalence of patients withHIV-Leishmaniasis Coinfection in Ethiopia • CID 2008:46 (1 June) • 1703
concordant HIV infection and VL (hereafter, “HIV-VL coin-
fection”) in Europe has fallen sharply since 1996, when anti-
retroviral treatment (ART) became standard. In India and par-
ticularly in Africa, HIV-VL coinfection is emerging. The AIDS
pandemic has expanded to rural areas where VL is endemic,
with cases of HIV-VL coinfection reported in 35 countries [7,
8], among which Ethiopia carries the greatest burden. Most
studies of HIV-VL coinfection originate in southern Europe
and are unlikely to be representative of the situation in East
Africa, where the parasite (L. donovani) is more pathogenicand
its comorbidities are different [9–17]. The Brazilian experience
of HIV-VL coinfection resembles that of Europe: high parasite
load, parasite dissemination to unusual sites, lower initial and
ﬁnal cure rates, greater susceptibility to drug toxicity, increased
risk of drug resistance, and higher rates of death and relapse
[18]. Information on HIV-VL coinfection in Africa is scarce;
known problems are similar to those mentioned above and
include a greater rate of post–kala-azar dermal leishmaniasis
[19–23]. In Europe, ART has reduced the incidence of VL [15],
has prolonged the intervals between relapses and reduced re-
lapse rates [11, 14, 24], and has improved survival [3].
Me ´decins Sans Frontie `res (MSF) has been giving treatment
to patients with VL in the Humera area of western Tigray, the
main region in Ethiopia where VL is endemic, since 1997. Our
VL-affected patient population consists mainly of male (190%)
migrant farm laborers who live and work unprotected from the
VL vector for several months among the cotton, sesame, and
sorghum ﬁelds. Having introduced ART in January 2004, we
wished to assess its impact and to identify determinants of VL
relapse and survival, to optimize patient care.
METHODS
Study design and population. HIV-VL–coinfected patients
were recruited from an integrated HIV and VL treatment pro-
gram at the MSF clinic in Humera, northwest Ethiopia, from
February 2003 through October 2006. The study group com-
prised patients who received a diagnosis of HIV-VL coinfection
at admission and patients who received a diagnosis of HIV/
AIDS at admission who had a history of VL and/or who de-
veloped VL during follow-up. All investigations and treatments
for all patients were free of charge.
HIV testing and treatment. All patients with VL were rou-
tinely offered voluntary HIV counseling and testing, generally
at 1–2 weeks after initiation of VL treatment, when the patient
was well enough to participate. HIV testing was done by 2
rapid diagnostic tests in parallel (HIV-Determine [Abbott Di-
agnostics] and Unigold [Trinity Biotech]) by use of venous
blood [25]. All positive test results were conﬁrmed in the lab-
oratory with a second blood sample by use of the same tests.
Patients with discordant test results were asked to return after
6 weeks; if the test results were again discordant, the test result
was considered negative. Patients with VL who were infected
with HIV were offered follow-up care in our clinic for HIV/
AIDS. We provided diagnosis and treatment of opportunistic
infections, Pneumocystis jiroveci pneumonia prophylaxis, tu-
berculosis treatment, psychosocial support,shelterforhomeless
patients, and a feeding program, as appropriate. Since January
2004, HIV-infected patients were offered ART if they had a
CD4
+ cell count !200 cells/mL, were well motivated for life-
long ART, and had not defaulted from the follow-up clinic.
ART was also offered to all HIV-infected patients with primary
VL and a CD4
+ cell count !350 cells/mL and to all coinfected
patients with VLrelapseirrespectiveofCD4
+cellcount.Generic
antiretroviral drugs were used: the ﬁrst-line regimen was la-
mivudine-stavudine-nevirapine, with alternative regimens of
lamivudine-zidovudine-nevirapine for stavudine toxicity and
lamivudine-stavudine-efavirenz with coadministration of ri-
fampicin for tuberculosis. Second-line regimens were not re-
quired during the study period.
Follow-up for patients with HIV/AIDS. CD4
+ cell counts
were determined (FacsCount ﬂow cytometer; Becton Dickin-
son) at the ﬁrst visit or, if the patient was receiving VL treat-
ment, after completion of VL treatment. Follow-up CD4
+ cell
counts were determined at 3–6 month intervals. Because of our
remote location, we could not routinely evaluate HIV-1 RNA
levels.
VL diagnosis and test of cure. We diagnosed VL as de-
scribed elsewhere [21]. We used the World HealthOrganization
case deﬁnition of VL [26]: a history of fever for 12 weeks
(malaria excluded) in combination with wasting and either
splenomegaly or lymphadenopathy. If patients met this case
deﬁnition, VL was conﬁrmed by a high titer (1:6400) on
Leishmania direct agglutination test (DAT) (Royal Tropical In-
stitute) [27] or by the ﬁnding of Leishmania amastigotes in
spleen or lymphnodeaspirates.Inpatientswithanintermediate
DAT titer (1:800–1:3200), aspiration was performed. Patients
with a negative DAT titer (1:400) were evaluated for alter-
native illnesses and were retested (by DAT and splenic aspirate)
if symptoms persisted. As was found previously in this pop-
ulation [21], there was no difference in mean DATtiterbetween
HIV-infected and -uninfected patients. Severelyillpatientswere
aspirated without delay, so that a diagnosis could be made as
quickly as possible. In patients with previous antileishmanial
treatment, VL was conﬁrmed by a positive aspirate result. A
test of cure by spleen or lymph node aspirate was done at the
end of treatment for all patients with VLrelapseandforpatients
with primary VL if the response to the treatmentwasuncertain.
VL treatment regimens. Primary VL was treated with so-
dium stibogluconate (SSG) (Albert David, Calcutta and Inter-
national Dispensary Association) at 20 mg/kg/day by intra-
muscular injection for 30 days. During November 2003–
September 2004, 33 men with VL participated in a randomized1704 • CID 2008:46 (1 June) • ter Horst et al.
trial of miltefosine versus SSG [21]; miltefosine was not avail-
able outside this clinical trial period. First relapses of VL were
treated with SSG for 40–60 days, depending on the results of
the test of cure. Second relapses of VL were treated either with
SSG for 40–60 days or with amphotericin B deoxycholate at 1
mg/kg intravenously every other day for 15–20 doses. Addi-
tional relapses were treated either with SSG or with ampho-
tericin B; occasionally, the 2 drugs were combined. Secondary
prophylaxis was not part of clinical management during the
study period.
Data entry andstatisticalanalysis. Demographicandclin-
ical data were collected for each patient from the patient’sHIV/
AIDS and VL medical records and were entered singly into an
Excel (Microsoft) spreadsheet. Statistical analyses were per-
formed using Stata (StataCorp). Hazard ratios for risk factors
for our outcomes of interest were estimated using Cox pro-
portional hazards regression. Factors for which there was an
association were then included in multivariate Cox regression
models to estimate the impact of ART on outcomes. We sep-
arated patients according to whethertheyreceivedART.Follow-
up began at initiation of ART or, for patients who did not
receive ART, when the patient registered atthetreatmentcenter.
Data on patients who defaulted or who transferred out of the
program were censored.
The primary outcomes were (1) VL relapse and (2) death
(all causes) during follow-up. We based survival analysis of VL
relapse on the interval from the start of follow-up to the ﬁrst
VL relapse during follow-up, irrespective of previous relapses.
Survival analysis of death was based on the interval from the
start of follow-up to death. Secondary outcomes were (1) mul-
tiple VL relapses and (2) ﬁrst episode of VL during follow-up.
The time to multiple VL relapses was taken as the intervalfrom
the start of follow-up to the ﬁrst of the patient’s relapsesduring
follow-up. Time to the ﬁrst episode of VL was the intervalfrom
the start of follow-up to the patient’s ﬁrst VL episode during
follow-up. As a ﬁnal outcome, we wished to establish whether
an immune reconstitution inﬂammatory syndrome (IRIS)
might have occurred. We deﬁned IRIS as the occurrence of the
ﬁrst episode of VL after initiation of ART, with a negativeresult
of a serological and/or parasitological test just before ART ini-
tiation and a positive result of a serological and/or parasito-
logical test after ART initiation. We also noted the occurrence
of tuberculosis in relation to the start of follow-up.
Ethics approval. Data were collected as part of routine pa-
tient care; no additional investigations were performed other
than those indicated for medical management. Ethics approval
was obtained from the MSF Ethical Review Board. Approval
was obtained from the Tigray regional health authorities for
publication of the data.
RESULTS
During the study period, 2782 patients with VL were given
treatment. Uptake of counseling and testing among patients
with VL was 70%, of whom 31% were infected with HIV. Of
these HIV-infected patients, 195 commenced ART during the
study period. Of the remaining HIV-infected patients (who did
not receive ART), 161 had sufﬁcient data for inclusion. Table
1 shows the demographic and clinical characteristics of the
patients with HIV-VL coinfection.
Factors associated with VL relapse. Baseline CD4
+ cell
count !100 cells/mL, tuberculosis coinfection, and previous VL
episodes were all risk factors for VL relapse (table 2). Among
patients who received ART, CD4
+ cell count reconstitution was
blunted among those with multiple relapses of VL, compared
with patients who did not have a VL relapse (ﬁgure 1).
In 18 relapses of VL (in 12 patients) the test of cure showed
failure to clear parasites; of the 18 relapses, 15 were followed
by further symptomatic VL relapse. One patient had “spon-
taneous” parasitological cure after a scantily positive test of
cure (grade 1), accompanied by a good CD4
+ cell count gain.
We sought to determine whether a threshold of CD4
+ cells
might protect against relapse of VL. Among 43 HIV-VL–coin-
fected patients receiving ART who had a ﬁrst VL relapse during
follow-up, 39 had a CD4
+ cell count recorded 2–7 months
before the relapse; of these 39 patients, 11 (28%) had CD4
+
cell counts 1200 cells/mL, and 4 had CD4
+ cell counts 1350
cells/mL. In 2 (5%) of the 39 patients, the CD4
+ cell count had
been sustained at 1200 cells/mL for 16 months preceding the
relapse. There were insufﬁcient patients to allow meaningful
analysis of intervals between events (e.g., from the ﬁrst VL
episode to the ﬁrst relapse, between successive relapses, orfrom
relapse to death) or of factors associated with these intervals.
Factors associated with death (all causes). Baseline or na-
dir CD4
+ cell count !100 cells/mL and 12 VL episodes were
associated with higher mortality among patients who received
ART and patients who did not receive ART; among the patients
who received ART, primary VL was also associated with higher
mortality (table 3).
Effect of ART onoutcomesduringfollow-up. Table4shows
the adjusted hazard ratios for the effects of ART, baseline CD4
+
cell count !100 cells/mL, and previous episodes of VL on the
primary and secondary outcomes. ART had a protective effect
on single or multiple relapses of VL, but there was no evidence
of an effect of ART on survival.
IRIS or primary acquisition of VL. Thirteen patients de-
veloped their ﬁrst lifetime VL episode after initiation of ART.
All had been evaluated for VL before initiation of ART, and 11
had documented negative DAT results (titer, !1:400) and/or
negative splenic aspirate test results; an additional 2 had in-
termediate serological test results (DAT titer, 1:400 but !1:HIV-Leishmaniasis Coinfection in Ethiopia • CID 2008:46 (1 June) • 1705
Table 1. Characteristics of patients who received and patients who did not re-
ceive antiretroviral treatment (ART).
Characteristic
Patients
without ART
() n p 161
Patients
with ART
() n p 195 P
a
Age, years
Mean (range) 31.3 (20–50) 33.5 (18–60) .01
b
Male sex 98.2 90.5 .003
Baseline CD4
+ cell count,
c cells/mL
300 37.3 2.4 !.001
200–299 18.6 12.1
100–199 14.4 38.6
0–99 29.7 47.0
Tuberculosis
None 64.2 41.4 !.001
Before study 25.3 39.8
After entry into study 8.0 16.2
Before and after entry into study 2.5 2.6
No. of VL episodes before entry into study
0 47.5 26.3 !.001
1 37.7 44.9
2 13.0 22.2
3 1.9 6.7
VL episode at entry into study 61.1 27.8 !.001
No. of VL episodes after entry into study
0 73.5 69.1 !.001
1 21.6 24.7
2 3.7 2.1
3 1.2 4.1
Follow-up status
Died 6.8 14.4 !.001
Defaulted 63.0 15.0
Transferred 11.7 4.1
Active 18.5 66.5
Follow-up time, months
Total 1003 1929
Mean 6.5 10.0 !.001
b
Median (range) 3.1 (0–36.5) 7.1 (0.5–33.5) !.001
d
NOTE. Data are % of patients, unless otherwise indicated.
a By x
2 test, unless otherwise indicated.
b By Student’s t test, with 354 df.
c Baseline data for CD4
+ cell count were missing for 28 patients who did receive ART and 44
patients who did not receive ART.
d By Kruskal-Wallis test, with 1 df.
1600) and negative aspirate results. All had documented high
DAT titers and/or positive parasitological test results after ini-
tiation of ART. The mean time at diagnosis of VL was 3 months
after initiation of ART (range, 12 days to 9 months). Their
mean CD4
+ cell count at ART initiationwas130cells/mL(range,
16–210 cells/mL). Their clinical picture was of classic VL, and
standard VL treatment was initiated in all cases. Signiﬁcant
CD4
+ cell count reconstitution after the primary VL episode
was documented in 8 patients: CD4
+ cell counts 150 cells/mL
at 6 months in 7 patients and a CD4
+ cell count of 37 cells/
mL at 6 months and 148 cells/mL at 12 months in 1 patient.
VL treatment outcomes were good among this group of pa-
tients; none died during treatment, 8 of 8 patients had a neg-
ative test of cure, and the remaining 5 patients showed a good
clinical response (test of cure was not performed). Two patients
subsequently died (after 3 months and 8 months) due to non-
VL causes. Relapse occurred in only 1 of the 12 patients with
sufﬁcient follow-up time (8 months) after the primary VL1706 • CID 2008:46 (1 June) • ter Horst et al.
Figure 1. Trends in CD4
+ cell counts for patientsreceivingantiretroviral
treatment (ART), including patients with multiple relapses of visceral
leishmaniasis (VL) and patients with no VL episode or a single VL episode
(primary or relapse). Bars represent 95% CIs.
Table 2. Risk factors for visceral leishmaniasis (VL) relapse during follow-up of patients who
received and patients who did not receive antiretroviral treatment (ART).
Risk factor
Unadjusted hazard ratio (95% CI)
Patients
without ART
Patients
with ART
Age 0.99 (0.94–1.04) 1.01 (0.97–1.04)
Sex (male vs. female) …
a 1.72 (0.53–5.57)
Tuberculosis
None 1.00 1.00
Before follow-up 1.34 (0.63–2.86) 1.28 (0.64–2.53)
After follow-up 0.56 (0.13–2.40) 1.18 (0.48–2.90)
Before and after follow-up 6.31 (1.42–28.01) 3.05 (0.88–10.56)
Baseline CD4
+ cell count, cells/mL
100 1.00 1.00
!100 2.05 (0.80–5.26) 2.50 (1.21–5.15)
Nadir CD4
+ cell count, cells/mL
100 1.00 1.00
!100 1.86 (0.72–4.78) 2.30 (1.24–4.26)
No. of VL episodes before follow-up
0 1.00 1.00
1 4.00 (1.64–9.77) 2.11 (0.79–5.66)
2 2.25 (0.68–7.41) 3.74 (1.40–10.02)
Interval from last VL episode to start of follow-up, months
!3 1.00 1.00
3–9 1.51 (0.40–5.68) 0.67 (0.31–1.43)
9 0.97 (0.18–5.27) 0.51 (0.20–1.27)
VL episode at start of follow-up 0.66 (0.34–1.30) 0.90 (0.46–1.75)
NOTE. VL, visceral leishmaniasis.
a None of 36 events involved female patients.
episode. Concomitant herpes zoster IRIS occurred in2patients,
and tuberculosis IRIS occurred in 2 other patients.
DISCUSSION
Our study represents the largest single-center cohort of HIV-
VL–coinfected patients reported to date, larger than all pre-
viously reported case series of HIV–L. donovani coinfection
combined. Ethiopian patients with HIV-VL coinfection,similar
to European patients coinfected with HIV and L. infantum,
have a poor prognosis; many patients have chronic relapsing
VL and early death. Factors associated with increased risk of
VL relapse were baseline CD4
+ cell count !100 cells/mL and a
history of VL and tuberculosis. Factors associated with in-
creased risk of death were baseline CD4
+ cell count !100 cells/
mL and VL during follow-up. ART reduced the risk of relapse
by ∼50%. Our data did not give meaningful information on
the effect of ART on the intervals between VL relapses,reported
as longer by some investigators in Europe [28].
Despite the large size of our study, we did not demonstrate
an impact of ART on survival, probably because our study
suffered from bias due to the substantial and disproportionateHIV-Leishmaniasis Coinfection in Ethiopia • CID 2008:46 (1 June) • 1707
Table 3. Risk factors for death (all causes) during follow-up of patients who
received and patients who did not receive antiretroviral treatment (ART).
Risk factor
Unadjusted hazard ratio (95% CI)
Patients
without ART
Patients
with ART
Age 1.13 (1.03–1.24) 0.99 (0.94–1.04)
Sex (male vs. female) …
a 1.05 (0.32–3.51)
Tuberculosis at any time 2.17 (0.54–8.72) 1.12 (0.52–2.41)
Baseline CD4
+ cell count, cells/mL
100 1.00 1.00
!100 13.82 (1.42–133.97) 3.20 (1.30–7.87)
Nadir CD4
+ cell count, cells/mL
100 1.00 1.00
!100 12.48 (1.29–121.01) 3.77 (1.61–8.84)
VL episode at start of follow-up 1.30 (0.31–5.45) 1.72 (0.80–3.71)
No. of VL episodes during follow-up
0 1.00 1.00
1 9.57 (1.07–85.90) 4.97 (2.09–11.86)
2 16.71 (1.71–163.44) 3.22 (1.01–10.23)
Primary VL during follow-up …
b 5.75 (2.25–14.71)
Single relapse during follow-up 3.48 (0.86–14.00) 2.19 (0.86–5.55)
Multiple relapse during follow-up 5.88 (1.37–25.31) 1.71 (0.50–5.77)
NOTE. VL, visceral leishmaniasis.
a None of 8 deaths involved female patients.
b None of 8 deaths involved patients with primary VL.
Table 4. Effect of antiretroviral treatment (ART) and other factors on outcomes during follow-up.
Outcome
Adjusted hazard ratio
a (95% CI)
ART (vs. no ART)
Baseline CD4
+ cell
count !100 cells/mL
(vs. 100 cells/mL)
2 Previous VL
episodes (vs. 0 or
1 episode)
Primary VL 0.77 (0.27–2.21) 0.91 (0.35–2.37) NA
Single relapse 0.46 (0.25–0.84) 1.60 (0.85–3.00) NA
Primary VL or single relapse 0.55 (0.33–0.92) 1.28 (0.75–2.19) NA
Multiple relapse 0.52 (0.12–2.18) 7.72 (1.54–38.77) 5.17 (1.41–18.99)
Single or multiple relapse 0.46 (0.26–0.82) 2.09 (1.19–3.67) 1.34 (0.70–2.55)
Any VL (primary, single, or multiple relapse) 0.56 (0.34–0.91) 1.66 (1.02–2.70) NA
Death 1.69 (0.56–5.12) 3.81 (1.55–9.36) 1.87 (0.66–5.29)
NOTE. NA, not applicable; VL, visceral leishmaniasis.
a Adjusted for each of the other factors shown plus age and tuberculosis.
number of patients who were lost to follow-up in the group
that did not receive ART. We could speculate (not unreason-
ably) that most of these patients would have died unless they
obtained treatment at the place to which they returned (pre-
sumably their place of origin), and ART might then show a
protective effect. Although ART reduced the risk of VL relapse,
22% of our patients who received ART experienced 1V L
relapse; these patients showed generally poor CD4
+ cell count
reconstitution despite good adherence to treatment. European
studies of HIV-VL–coinfected patients have reported similarly
poor CD4
+ cell count reconstitution but have attributed this
to poor adherence to ART [24]. Thresholds for safe discontin-
uation of secondary prophylaxis for patients with HIV and L.
infantum VL have been suggested as CD4
+ cell counts of 200
cells/mL [29] and 350 cells/mL [30]. In our study, VL relapses
were sometimes seen despite high CD4
+ cell counts—in 28%
of ﬁrst relapses during follow-up, theprecedingCD4
+cellcount
was 1200 cells/mL, and, in 10% of ﬁrst relapses, it was 1350
cells/mL. Our data suggest that a high CD4
+ cell count is re-
quired to prevent relapse of L. donovani infection. This is con-1708 • CID 2008:46 (1 June) • ter Horst et al.
Figure 2. Relapseprobabilitycurvesforpatientsreceivingantiretroviral
treatment (ART), which show the inﬂuence of the nadir CD4
+ cell count
and previous episodes of visceral leishmaniasis (VL) on the probability
of VL relapse within 1 year.
sistent with the observation that L. donovani is a virulent, an-
throponotic species, whereas L. infantum has little virulencefor
immunocompetent humans beyond early childhood. We con-
sider that the lack of clearance of Leishmania parasites in our
patients holds the patient in a state of immune suppression;
hence, they are unable to regain cellular immunity (despite
good antiviral efﬁcacy of ART). This leads to recrudescence of
parasites and relapses.
We reported 18 instances of failure to clear parasites, despite
prolonged treatment with SSG and amphotericin B, suggesting
that development of secondary resistanceinAfricanL.donovani
can occur with relative ease. VL treatment failure was almost
always followed by further symptomatic VL episodes, dem-
onstrating the importance of achieving an initialparasitological
cure. In HIV-VL–coinfected patients, the most likely way of
achieving this is by combination VL therapy.Inanalysesbeyond
the scope of this study, we found that patients receiving ART
who have a history of VL have a mortality rate twice as high
as that of patients receiving ART from the same treatment
center who do not have VL ( ), controlling for age and n p 2111
baseline CD4
+ cell count (HR, 2.02; 95% CI, 1.21–3.37).
We consider that there is need for long-term, maintenance
antileishmanial treatment for individuals at high risk of VL
relapse once a negative test of cure is achieved. Such patients
might be identiﬁed by the factors we found—for example, a
patient with baseline CD4
+ cell count !100 cells/mL and 3
previous VL episodes would have a 56% chance of relapsing
within 1 year (ﬁgure 2). Such patients might then be eligible
for secondary prophylaxis (e.g., with pentamidine). It is not
yet clear after what VL disease–free interval or at what CD4
+
cell count level patients are free of signiﬁcant risk of VL relapse,
but we hope to address these questions in the future. Limited
evidence is available for secondary prophylaxis for patientswith
HIV and L. infantum VL. In a randomized trial of 17 patients,
50% of the group that received secondary prophylaxis (3 mg
of amphotericin Blipid complexperkgevery21days)remained
relapse free at 1 year, compared with 22% of the group without
prophylaxis [31]. A retrospective study of 46 patients reported
probabilities of patients remaining relapse-free at 1 year of 9%
without secondary prophylaxis, 21% with allopurinol, and93%
with pentavalent antimony [32]. Six patients in Spain received
pentamidine at 4 mg/kg every 2 or 4 weeks (3 patients in each
group) as secondary prophylaxis. No relapses were observed
during a mean follow-up of 8 months (range, 3–12 months)
[33]. Pentamidine might be a useful drug for secondary pro-
phylaxis for VL; it has been used safelyassecondaryprophylaxis
against Pneumocystis carinii pneumonia [34].
We report an important ﬁnding of 13 patients that had a
ﬁrst VL episode after initiation of ART; these patients could
be manifesting VL IRIS. Before this study, 6 possible cases of
VL IRIS have been reported, all from the Mediterraneanregion
[35].
Our ﬁndings lead us to make 5 recommendations for the
care of HIV-VL–coinfected patients in Africa. First, given the
clear beneﬁts of ART, HIV testing should be widely applied
using an opt-out strategy. Second, in Ethiopia but not in other
countries, VL has been classiﬁed as an AIDS-deﬁning oppor-
tunistic infection (in Ethiopian national HIV guidelines). We
consider that VL should be an AIDS-deﬁning illnessinallcoun-
tries and a valid entry point to ART irrespective of CD4
+ cell
count. This may help to reduce VL relapse rates. Third, sec-
ondary VL prophylaxis is necessary for individuals at high risk
of relapse despite ART. Fourth, parasitological clearance seems
to be a crucial end point to VL treatment. Finally, high rates
of treatment failure, possibly leading to development of resis-
tant parasites, indicate that combination therapy, instead of
monotherapy, should be used to treat HIV-VL coinfection. In
selecting a combination regimen, it should be kept in mind
that SSG monotherapy has an unacceptable mortality rate in
HIV-VL–coinfected patients [21] and, theoretically,mayinduce
an increase in HIV-1 virus replication [36]. We look forward
to the licensing in Ethiopia and in other countries of safer
drugs for patients with HIV-VL coinfection (e.g., miltefosine,
paromomycin, and liposomal amphotericin B), preferably to
be used in combination.
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